Pfizer, Abbott tank after ban on Corex, Phensedyl
Abbott India shares fell 1.98 per cent to hit a low of Rs 4,755 after ban on its Phensedyl syrup. Abbott is reviewing the notification, the Economic Times reported.14-03-2016
14-03-2016
Abbott India MD Rehan A Khan resigns
The resignation shall be effective close of business hours on April 30, 201601-03-2016
Change in Directors
Abbott India Ltd has informed BSE that :1. Mr Rehan A. Khan has vide his letter dated February 29, 2016 tendered resignation as the Managing Director and Director of the Company to pursue career opportunity overseas. His resignation shall be effective close of business hours on April 30, 2016.2. Mr Kaiyomarz Marfatia has ceased to be a Whole-Time Director of the Company upon completion of his term with effect from February 29, 2016....29-02-2016
Healthy growth
Abbott India's success comes from strong brands and a focus on the consumer10-02-2016
Financial Results & Limited Review Report for Dec 31, 2015
Abbott India Ltd has informed BSE about :1. Financial Results for the period ended December 31, 2015 (Standalone)2. Limited Review Report for the period ended December 31, 2015 (Standalone)01-02-2016
Board Intimation for Results & Closure of Trading Window
Abbott India Ltd has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on February 01, 2016, inter alia, to consider and approve the text of Unaudited Financial Results of the Company for the quarter and nine months ended on December 31, 2015, along with the Limited Review Report of the Statutory Auditors thereon as required under Regulation 33 of the said Regulations....22-01-2016
Shareholding for the Period Ended December 31, 2015
Abbott India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2015. For more details, kindly Click here19-01-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015
Abbott India Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2015, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.12-01-2016
Authorised KMPs to determine materiality of events/information
Abbott India Ltd has informed BSE regarding "Authorised Key Managerial Personnel to determine materiality of events/information".07-12-2015
Abbott India Q2 net profit down 3% at Rs61.70 crore
Standalone income from operations rose to Rs645.06 crore for second quarter against Rs588.71 crore for the same period a year ago06-11-2015